ArticleDrugs2001
Omalizumab.
Article in Drugs, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 87 citations in OpenAlex.
- QX008N, an Anti-TSLP Monoclonal Antibody: Pharmacokinetics, Tolerability, and Immunogenicity in Healthy Chinese Subjects.Clinical and translational science · 2026Trial
- Omalizumab-Associated Post-Injection Urticaria Exacerbation and Urticaria-Related Adverse Reactions During Treatment for Chronic Urticaria: A Scoping Review.Life (Basel, Switzerland) · 2026Review
- Review
- Immune-Targeted Therapies for Depression: Current Evidence for Antidepressant Effects of Monoclonal Antibodies.The Journal of clinical psychiatry · 2024Review
- Effect of omalizumab on inflammatory markers in COVID-19: an exploratory analysis of the COVID-19 immunologic antiviral therapy with omalizumab (CIAO) trial.Frontiers in medicine · 2024Article
- A fully human anti-c-Kit monoclonal antibody 2G4 inhibits proliferation and degranulation of human mast cells.Molecular and cellular biochemistry · 2023Article
- The Role ofInternational journal of molecular sciences · 2022Review
- The Acari Hypothesis, III: Atopic Dermatitis.Pathogens (Basel, Switzerland) · 2022Article
- Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma.Journal of personalized medicine · 2022Review
- Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma.The Korean journal of internal medicine · 2021Article
- Anti-IgE Treatment for Disorders Other Than Asthma.Frontiers in medicine · 2017Review
- Role of biologics in intractable urticaria.Biologics : targets & therapy · 2015Review
- Immunotherapy in allergy and cellular tests: state of art.Human vaccines & immunotherapeutics · 2014Review
- New strategies with anti-IgE in allergic diseases.The World Allergy Organization journal · 2014Review
- Anti-immunoglobulin e therapy.The World Allergy Organization journal · 2008Article
- Omalizumab in asthma: approval and postapproval experience.Clinical reviews in allergy & immunology · 2005Review
- Biologicals in Treatment of Chronic Urticaria: A Narrative Review.Indian dermatology online journalReview
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
* Omalizumab is a recombinant humanised monoclonal antibody which specifically binds to the C epsilon3 domain of immunoglobulin (Ig) E, the site of high-affinity IgE receptor binding. * Improvements in asthma symptoms and health-related quality-of-life, and a significant reduction in the frequency of asthma exacerbations were seen in allergic asthmatic patients treated with omalizumab. * Omalizumab was also effective in the treatment of children with allergic asthma demonstrating improvements in health-related quality-of-life and significant dosage reductions of inhaled corticosteroids. * Administration of omalizumab to patients with allergic rhinitis resulted in a rapid dose-dependent suppression of serum free IgE levels. * Omalizumab significantly improved health-related quality-of-life and nasal symptoms in patients with seasonal allergic rhinitis. Antihistamine requirements were also significantly reduced following treatment. * Adverse events were infrequent in clinical trials of omalizumab, and not significantly different from placebo. The most frequent drug-related event was mild to moderate urticaria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.